Artificial intelligence and advanced computational platforms are increasingly transforming drug discovery and biomanufacturing. Biotx AI, a German startup, enhances genome-wide association data analysis with Mendelian randomization and machine learning to identify drug targets and repurpose drugs, exemplified by collaborations for ADHD and heart failure. Dalriada expanded its iCLASS platform with computational partnerships to uncover cryptic drug targets. Agentic AI architectures integrate real-time sensor data with process simulations, exemplified by the SIC platform, enabling autonomous biomanufacturing control and optimization, addressing industry challenges in scale-up and fragmented data systems.